AbCellera Biologics Inc. (ABCL)

NASDAQ: ABCL · IEX Real-Time Price · USD
4.490
+0.200 (4.66%)
At close: Mar 27, 2024, 4:00 PM
4.500
+0.010 (0.22%)
Pre-market: Mar 28, 2024, 5:32 AM EDT

Company Description

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development.

Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies.

The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.

It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets, as well as strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions.

The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc.
AbCellera Biologics logo
Country Canada
Founded 2012
IPO Date Dec 11, 2020
Industry Biotechnology
Sector Healthcare
Employees 586
CEO Dr. Carl L.G. Hansen Ph.D.

Contact Details

Address:
2215 Yukon Street
Vancouver, A1 V5Y 0A1
British Columbia, Canada
Phone (604) 559-9005
Website abcellera.com

Stock Details

Ticker Symbol ABCL
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $20.00
CIK Code 0001703057
CUSIP Number 00288U106
ISIN Number CA00288U1066
SIC Code 2834

Key Executives

Name Position
Dr. Carl L.G. Hansen Ph.D. Chief Executive Officer, President and Chairperson
Andrew Booth M.B.A. Chief Financial Officer
Dr. Veronique Lecault Ph.D. Chief Operating Officer and Director
Tryn T. Stimart Esq., J.D., M.Sc. Chief Legal Officer, CCO, Compliance Officer, Corporate Secretary and Privacy Officer
Neil Aubuchon B.A., M.B.A. Chief Commercial Officer
Marcie Thiessen CPA, CGA Senior Director of Finance and Accounting
Dr. Ester Falconer Ph.D. Chief Technology Officer
Kathleen Reid B.A. Head of Corporate Communications
Graham Craig M.Sc. Director of Corporate Development
Murray McCutcheon Ph.D. Senior Vice President of Partnering

Latest SEC Filings

Date Type Title
Feb 23, 2024 8-K Current Report
Feb 20, 2024 S-8 Securities to be offered to employees in employee benefit plans
Feb 20, 2024 10-K Annual Report
Feb 20, 2024 8-K Current Report
Feb 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 29, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 28, 2023 8-K Current Report
Nov 2, 2023 10-Q Quarterly Report
Nov 2, 2023 8-K Current Report